Tight interplay between the Ca2+ affinity of the cardiac SERCA2 Ca2+ pump and the SERCA2 expression level

Cell Calcium

Volumn 42, Issue 3, 2007, Pages 281-289

  Vangheluwe, Peter ^a   Schuermans, Marleen ^a   Raeymaekers, Luc ^a   Wuytack, Frank ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Cardiac hypertrophy; Phospholamban; Sarcoplasmic reticulum Ca2+ ATPase

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ADENOSINE TRIPHOSPHATASE (CALCIUM) 2A; ADENOSINE TRIPHOSPHATASE (CALCIUM) 2B; ADENOSINE TRIPHOSPHATE; ISOPROTEIN; PHOSPHOLAMBAN; UNCLASSIFIED DRUG; ATP2A2 PROTEIN, MOUSE; CALCIUM; CALCIUM BINDING PROTEIN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ANIMAL TISSUE; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE EXPRESSION; HEART HYPERTROPHY; HEART VENTRICLE REMODELING; HETEROZYGOSITY; HOMOZYGOSITY; MOLECULAR MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; SARCOPLASMIC RETICULUM; TRANSGENE; ANIMAL; GENETICS; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HUMAN; METABOLISM; MOUSE MUTANT;

MUS;

ANIMALS; CALCIUM; CALCIUM-BINDING PROTEINS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MICE; MICE, KNOCKOUT; MYOCARDIUM; PROTEIN ISOFORMS; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; TRANSGENES; VENTRICULAR REMODELING;

EID: 34447502531     PISSN: 01434160     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ceca.2007.01.001     Document Type: Article

References (26)

1. del Monte F., and Hajjar R.J. Targeting calcium cycling proteins in heart failure through gene transfer. J. Physiol. 546 (2003) 49-61
2. Dash R., Kadambi V., Schmidt A.G., et al. Interactions between phospholamban and beta-adrenergic drive may lead to cardiomyopathy and early mortality. Circulation 103 (2001) 889-896
3. Schmitt J.P., Kamisago M., Asahi M., et al. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 299 (2003) 1410-1413
4. Haghighi K., Kolokathis F., Gramolini A.O., et al. A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 1388-1393
5. 2+ pump, cause Darier disease. Nat. Genet. 21 (1999) 271-277
6. Tavadia S., Tait R.C., McDonagh T.A., and Munro C.S. Platelet and cardiac function in Darier's disease. Clin. Exp. Dermatol. 26 (2001) 696-699
7. Mayosi B.M., Kardos A., Davies C.H., et al. Heterozygous disruption of SERCA2a is not associated with impairment of cardiac performance in humans: implications for SERCA2a as a therapeutic target in heart failure. Heart 92 (2006) 105-109
8. 2+-ATPase isoform 2 (SERCA2) gene. J. Biol. Chem. 274 (1999) 2556-2562
9. 2+ homeostasis and cardiomyocyte function. J. Biol. Chem. 275 (2000) 38073-38080
10. 2+ transport ATPase isoforms SERCA2a and SERCA2b are targeted to the same sites in the murine heart. Cell Calcium 34 (2003) 457-464
11. 2+-ATPase 2 isoform (SERCA2c). Biochem. J. 395 (2006) 249-258
12. 2+ ATPase 2 (SERCA2) activity: cell biological implications. Cell Calcium 38 (2005) 291-302
13. 2+-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heart. Circ. Res. 89 (2001) 838-846
14. Greene A.L., Lalli M.J., Ji Y., et al. Overexpression of SERCA2b in the heart leads to an increase in sarcoplasmic reticulum calcium transport function and increased cardiac contractility. J. Biol. Chem. 275 (2000) 24722-24727
15. 2+ affinity can lead to severe cardiac hypertrophy, stress intolerance and reduced life span. J. Mol. Cell Cardiol. 41 (2006) 308-317
16. MacLennan D.H., and Kranias E.G. Phospholamban: a crucial regulator of cardiac contractility. Nat. Rev. Mol. Cell Biol. 4 (2003) 566-577
17. Dorn II G.W., Robbins J., and Sugden P.H. Phenotyping hypertrophy: eschew obfuscation. Circ. Res. 92 (2003) 1171-1175
18. Suzuki M., Carlson K.M., Marchuk D.A., and Rockman H.A. Genetic modifier loci affecting survival and cardiac function in murine dilated cardiomyopathy. Circulation 105 (2002) 1824-1829
19. Koss K.L., Grupp I.L., and Kranias E.G. The relative phospholamban and SERCA2 ratio: a critical determinant of myocardial contractility. Basic. Res. Cardiol. 92 Suppl 1 (1997) 17-24
20. 2+ pump expression in cardiac and smooth muscle. Biochem. J. 338 (1999) 167-173
21. 2+ pump mRNA decay by nuclear proteins. Biochem. J. (2005)
22. Braz J.C., Gregory K., Pathak A., et al. PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat. Med. 10 (2004) 248-254
23. Kadambi V.J., Ponniah S., Harrer J.M., et al. Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice. J. Clin. Invest. 97 (1996) 533-539
24. 2+ loads only. Circ. Res. 92 (2003) 881-887
25. Haghighi K., Kolokathis F., Pater L., et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J. Clin. Invest. 111 (2003) 869-876
26. 2+ affinity in cardiac function. Biochim. Biophys. Acta (BBA)-Mol. Cell Res. 1763 (2006) 1216-1228